Unknown PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT05226429

UNAIR Inactivated COVID-19 Vaccine

Safety and Immunogenicity of UNAIR Inactivated COVID-19 Vaccine in Healthy Populations Aged 18 Years and Above (Phase I/II)

Sponsor: Bioxis Pharmaceuticalls

Conditions COVID-19 Pandemic Vaccine Reaction

Interventions CoronaVac Biofarma COVID-19 Vaccine UNAIR Inactivated COVID-19 Vaccine

Updated 7 times since 2022 Last updated: Jun 13, 2023 Started: Feb 8, 2022 Primary completion: Apr 6, 2023 Completion: Jul 6, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates COVID-19 Pandemic and Vaccine Reaction and is currently ongoing. Bioxis Pharmaceuticalls leads this study, which shows 7 recorded versions since 2022 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

7 versions recorded

Jun 2025 — Present [monthly]

Unknown PHASE1/PHASE2

Status: Recruiting → Unknown
Mar 2025 — Jun 2025 [monthly]

Recruiting PHASE1/PHASE2
Sep 2024 — Mar 2025 [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jul 2023 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2

▶ Show 2 earlier versions

Sep 2022 — Jul 2023 [monthly]

Recruiting PHASE1_PHASE2
Mar 2022 — Sep 2022 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Feb 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bioxis Pharmaceuticalls
Dr. Soetomo General Hospital
Indonesia-MoH
Universitas Airlangga

Data source: Dr. Soetomo General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Surabaya, Indonesia